Back

Reduction of heart failure hospitalization-related healthcare costs for transthyretin amyloid cardiomyopathy patients on treatment

29 August 2025 (07:00 - 18:00)
Organised by: Logo
Congress Presentation Part of: Trends and challenges in heart failure management Epidemiology, Prognosis, Outcome ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Dhruvil Patel

Rutgers Robert Wood Johnson Medical School, New Brunswick (United States of America)

7 More presentations in this session

Presentation thumbnail
Prediction model of rehospitalization in heart failure with preserved and mildly-reduced ejection fraction: the AD2NER risk score
Doctor F. Stoiculescu (Craiova, RO)
Abstract Slides Video
Presentation thumbnail
Prevalence, prognosis, and factors associated with heart failure with improved ejection fraction: single centre experience
Doctor M. Vidak (Zagreb, HR)
Abstract Slides Video
Presentation thumbnail
Prognostic impact of cardio-renal-anemia syndrome in heart failure - a report from the JROADHF database.
Doctor E. Noda (Fukuoka, JP)
Abstract Slides Video
Presentation thumbnail
Heart failure hospitalization and mapping of post-discharge care: insights from a slovakian cohort study
Mr M. Selvek (Bratislava, SK)
Abstract Slides Video
Presentation thumbnail
Delay in assistance effects in cardiology consultation following primary care physician referral in heart failure patients
Professor J. Gonzalez Juanatey (Santiago de Compostela, ES)
Abstract Slides Video

Access the full session

Session thumbnail
Trends and challenges in heart failure management

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025
You may be interested in
thumbnail
Congress Presentation
Disease progression among patients receiving tafamidis for transthyretin amyloidosis with cardiomyopathy in a real-world setting
thumbnail
Congress Presentation
Survival in a contemporary, real-world, matched cohort of patients with transthyretin amyloid cardiomyopathy treated vs not treated with tafamidis
thumbnail
Congress Presentation
Tafamidis for the treatment of transthyretin cardiac amyloidosis (ATTR-CM) - Real-world data from a tertiary center.

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources